Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial ; volume:23 ; number:1 ; day:25 ; month:9 ; year:2021 ; pages:1-11 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (25.9.2021), 1-11, 12.2021
- Urheber
-
Fleischmann, Roy M.
Alvarez, Daniel F.
Bock, Amy E.
Cronenberger, Carol
Vranic, Ivana
Zhang, Wuyan
Alten, Rieke
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-021-02626-4
- URN
-
urn:nbn:de:101:1-2021121618221476408308
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fleischmann, Roy M.
- Alvarez, Daniel F.
- Bock, Amy E.
- Cronenberger, Carol
- Vranic, Ivana
- Zhang, Wuyan
- Alten, Rieke
- SpringerLink (Online service)
Ähnliche Objekte (12)
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh